BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
epimedium and smilax share 4415 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.678 means 68% of the combined target set is bound by both compounds. The IDF-weighted score of 0.649 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do epimedium and smilax have in common?
epimedium and smilax share 4415 molecular targets with a Jaccard similarity of 68%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can epimedium and smilax be combined?
epimedium and smilax share 4415 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: epimedium or smilax?
In the BiohacksAI corpus: epimedium has 138 PubMed-indexed studies, smilax has 143 studies.